Last updated: February 20, 2026
What is NDC 71288-0450?
NDC 71288-0450 refers to a specific pharmaceutical product classified under the National Drug Code (NDC) system. The code corresponds to Novo Nordisk's Ozempic (semaglutide) injectable for type 2 diabetes management. This medication gained FDA approval in June 2017 and has since experienced rapid market penetration, becoming a leading GLP-1 receptor agonist.
Market Overview
Current Market Dynamics
- Market Size (2022): The global GLP-1 receptor agonist market was valued at approximately USD 8.5 billion.
- Key Competitors: Eli Lilly (tirzepatide), AstraZeneca (Rybelsus), and Novo Nordisk (Ozempic, Wegovy).
- Growth Rate: Compound annual growth rate (CAGR) projected at 20% through 2027 (Grand View Research).
Key Drivers
- Efficacy: Demonstrated superiority in glycemic control and weight loss over traditional therapies.
- FDA Approvals: Expanded indications include obesity management, increasing patient population.
- Clinician Adoption: Strong clinical trial data and consistent prescribing patterns.
Regulatory Landscape
- Expanded Uses: FDA approval for weight management (Wegovy) in 2021.
- Reimbursement Trends: Increasing Medicare and private insurer coverage, reducing patient out-of-pocket costs.
Distribution Channels
- Hospitals and clinics: Primary settings, with direct physician prescriptions.
- Pharmacies: Major retail and specialty pharmacies dominate dispensing.
Pricing Analysis
Current Pricing (2022)
| Region |
Average Wholesale Price (AWP) |
Estimated Out-of-Pocket Cost (with insurance) |
| United States |
USD 1,000 per 4-week supply |
USD 20-50 (after insurance) |
| European Markets |
EUR 700-900 per pack |
EUR 15-40 (varies by country) |
| Other markets |
USD 800-1,200 per 4-week supply |
Variable, generally higher in low-income regions |
Price Trends (2017-2022)
- Initial Launch Price: Approx. $870 per 4-week supply.
- Price Increases: Incremental hikes of 3%-5% annually, influenced by manufacturing costs and demand.
- Generics and Biosimilars: No biosimilars introduced yet, but patent expirations expected by 2027 could influence future pricing.
Price Projections (2023-2030)
| Year |
Estimated Price Range (USD) |
Key Factors Impacting Price |
| 2023 |
$1,020 - $1,100 per 4-week |
Increased demand, supply chain stability |
| 2025 |
$1,100 - $1,200 |
Potential entry of biosimilars in late 2024 |
| 2027 |
$900 - $1,000 |
Patent expiry, biosimilar competition |
| 2030 |
$800 - $950 |
Market saturation, cost containment measures |
Influencing Factors
- Patent Expiry: Estimated by 2027, opening pathways for biosimilars.
- Manufacturing Costs: Likely to decrease with process optimizations and biosimilar competition.
- Market Penetration: Expansion into emerging markets could drive volume but may pressure pricing.
- Regulatory Changes: Potential approvals for new indications or formulations can alter pricing structures.
Strategic Considerations for Stakeholders
- Investors: Patience until patent expiry may yield significant price reductions driven by biosimilar competition.
- Manufacturers: Focus on innovation and cost reduction to maintain margins amidst impending biosimilar entries.
- Healthcare Providers: Consider the cost-benefit profile of Ozempic versus newer entrants or generics.
Key Takeaways
- Ozempic currently commands a premium price driven by its clinical efficacy and market dominance.
- The market is set for sustained growth, with prices likely to plateau or decrease modestly from mid-decade onward due to biosimilar pressures.
- Influencing factors include patent expirations, biosimilar manufacturing, regulatory policies, and regional pricing strategies.
FAQs
Q1: When will biosimilars for Ozempic likely enter the market?
A1: Biosimilars are expected around 2027, aligned with patent expiration.
Q2: How will biosimilar entries impact the price of NDC 71288-0450?
A2: Biosimilar competition will pressure prices downward, potentially reducing costs by 30-50%.
Q3: What markets present the highest growth opportunities?
A3: Emerging economies in Asia-Pacific and Latin America, where diabetes prevalence is rising.
Q4: Are there regulatory hurdles for biosimilar approval?
A4: Yes, biosimilar approval requires demonstrating similarity in safety, efficacy, and immunogenicity, which can delay market entry.
Q5: How does insurance coverage affect patient out-of-pocket costs?
A5: Insurance significantly lowers costs in the US, with coverage expanding for weight management indications, improving access.
References
- Grand View Research. (2022). GLP-1 receptor agonists market size, share & trends analysis.
- FDA. (2021). FDA approves Wegovy for chronic weight management.
- IQVIA. (2022). Global prescribing trends for diabetes medications.
- Pharmaceutical Technology. (2022). Biosimilar development and regulatory pathways.
- Statista. (2022). Diabetes prevalence and market data by region.
